Get the Stockscreener App
5.78
3.67%
-0.22
After Hours:
6.12
0.34
+5.88%
Solid Biosciences Inc stock is traded at $5.78, with a volume of 2.17M.
It is down -3.67% in the last 24 hours and up +77.30% over the past month.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
See More
Previous Close:
$6.00
Open:
$6.13
24h Volume:
2.17M
Relative Volume:
1.13
Market Cap:
$441.12M
Revenue:
$14.79M
Net Income/Loss:
$-102.44M
P/E Ratio:
-1.9013
EPS:
-3.04
Net Cash Flow:
$-91.73M
1W Performance:
+43.42%
1M Performance:
+77.30%
6M Performance:
-41.91%
1Y Performance:
-42.43%
1-Day Range:
$5.50
$6.149
1-Week Range:
$5.04
$7.20
52-Week Range:
$2.88
$15.05
Solid Biosciences Inc Stock (SLDB) Company Profile
Name
Solid Biosciences Inc
Sector
Industry
Phone
617-337-4680
Address
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
5.78 | 441.12M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-13-24 | Initiated | Wedbush | Outperform |
| Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-15-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | William Blair | Outperform |
| Mar-15-24 | Initiated | Citigroup | Buy |
| Mar-14-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | Piper Sandler | Neutral |
| May-27-21 | Initiated | Jefferies | Buy |
| Mar-16-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Jan-08-21 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jul-28-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-07-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-19 | Initiated | Evercore ISI | Outperform |
| Aug-29-19 | Downgrade | Citigroup | Neutral → Sell |
| Aug-19-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-16-19 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| May-14-19 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-14-19 | Downgrade | Goldman | Neutral → Sell |
| Feb-08-19 | Upgrade | Citigroup | Sell → Neutral |
| Feb-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-06-18 | Initiated | Citigroup | Sell |
| Sep-06-18 | Initiated | Credit Suisse | Neutral |
View All
Solid Biosciences Inc Stock (SLDB) Latest News
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here? - MSN
Bain Capital life sciences invests $4.03 million in Solid Biosciences By Investing.com - Investing.com
Solid Biosciences sees $20.15m stock purchase by Perceptive Advisors - Investing.com
Research Analysts Issue Forecasts for SLDB FY2025 Earnings - MarketBeat
Wedbush Increases Earnings Estimates for Solid Biosciences - MarketBeat
Chardan Capital Forecasts Strong Price Appreciation for Solid Biosciences (NASDAQ:SLDB) Stock - Defense World
Solid Biosciences’ stock soars on early success in DMD gene therapy trial - MSN
Solid Biosciences (NASDAQ:SLDB) Given New $16.00 Price Target at Chardan Capital - MarketBeat
Solid Biosciences’ $200 Million Common Stock Offering - Global Legal Chronicle
Wall Street’s Top Picks: Solid Biosciences, Wingstop, and Diamondback Energy - PUNE.NEWS
Wedbush Adjusts Price Target on Solid Biosciences to $18 From $16, Keeps Outperform Rating - Marketscreener.com
Solid Biosciences surges on Duchenne therapy success - The Pharma Letter
Solid Biosciences shares gain on JMP Market Outperform rating By Investing.com - Investing.com South Africa
Solid Biosciences shares gain on JMP Market Outperform rating - Investing.com India
Solid Biosciences CFO Kevin Tan sells $12,529 in stock By Investing.com - Investing.com Nigeria
Solid Biosciences' Retail Following Swells Amid Stock's Best Run In A Year — What's Behind The Move? - MSN
Solid Biosciences' SWOT analysis: gene therapy stock poised for pivotal year - Investing.com Nigeria
Solid Biosciences Inc. (NASDAQ:SLDB) Receives $15.30 Average PT from Analysts - MarketBeat
Solid Biosciences Announces Pricing of Underwritten Offering - GlobeNewswire
Solid Biosciences CTO Herzich sells $10,644 in stock By Investing.com - Investing.com Australia
Solid Biosciences COO David Howton sells shares worth $22,021 By Investing.com - Investing.com Australia
Solid Biosciences chief regulatory officer sells shares for $12,192 By Investing.com - Investing.com South Africa
Solid Biosciences price target raised to $16 from $15 at Chardan - TipRanks
Solid Biosciences chief medical officer sells $12,893 in stock By Investing.com - Investing.com Canada
Solid Biosciences CEO Alexander Cumbo sells $45,005 in stock By Investing.com - Investing.com Australia
Solid Biosciences’ Gene Therapy SGT-003 Produces Microdystrophin Expression in Patients With DMD - CGTLive™
Solid Biosciences CFO Kevin Tan sells $12,529 in stock - Investing.com
Solid Biosciences CEO Alexander Cumbo sells $45,005 in stock - Investing.com
Solid Biosciences CTO Herzich sells $10,644 in stock - Investing.com
Solid Biosciences COO David Howton sells shares worth $22,021 - Investing.com India
Solid Biosciences Shares Up After Positive Results From Duchenne Drug Study, Prices $200 Million Offering - Marketscreener.com
Solid Biosciences stock soars on promising Duchenne therapy data - Investing.com India
Early DMD gene therapy data powers Solid Bio stock surge - FirstWord Pharma
Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data - Benzinga
As part of turnaround, Solid Bio reports promising initial data for Duchenne gene therapy - Endpoints News
Solid says early data suggest ‘differentiated’ Duchenne gene therapy - BioPharma Dive
Solid Biosciences sets $200 million stock and warrant offering By Investing.com - Investing.com Nigeria
Solid Biosciences jumps on early-stage data from gene therapy - TradingView
Biotech Boom: Solid Biosciences (SLDB) Stock Skyrockets On Positive Developments - Stocks Telegraph
Morning Brew: Marjorie Taylor Greene's Stock Moves and Solid Biosciences' Surge - GuruFocus.com
Duchenne gene therapy from Solid Biosciences produces promising results in early study - STAT
Solid Bio stock rises on data for Duchenne drug (SLDB:NASDAQ) - Seeking Alpha
Solid soars as early DMD gene therapy data beat expectations - Fierce Biotech
Solid Biosciences sets $200 million stock and warrant offering - Investing.com India
Solid Biosciences Reports Positive Initial Clinical Data from SGT-003 -February 18, 2025 at 06:59 am EST - Marketscreener.com
Massive $200M Capital Raise: Elite Healthcare Investors Back Solid Biosciences Growth Plan - StockTitan
Solid Biosciences reports initial clinical data from INSPIRE DUCHENNE trial - TipRanks
Solid Biosciences Reports Promising Initial Data from Phase 1/2 INSPIRE DUCHENNE Trial for SGT-003 in Duchenne Muscular Dystrophy - Nasdaq
Solid Biosciences Reports Positive Initial Clinical Data - GlobeNewswire
Clinical Trial Breakthrough: Revolutionary Gene Therapy Achieves 110% Dystrophin in Duchenne Patients - StockTitan
Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Solid Biosciences Inc Stock (SLDB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):